PL369019A1 - Sposób leczenia zwłóknienia torbielowatego - Google Patents

Sposób leczenia zwłóknienia torbielowatego

Info

Publication number
PL369019A1
PL369019A1 PL02369019A PL36901902A PL369019A1 PL 369019 A1 PL369019 A1 PL 369019A1 PL 02369019 A PL02369019 A PL 02369019A PL 36901902 A PL36901902 A PL 36901902A PL 369019 A1 PL369019 A1 PL 369019A1
Authority
PL
Poland
Prior art keywords
cystic fibrosis
treat cystic
treat
fibrosis
cystic
Prior art date
Application number
PL02369019A
Other languages
English (en)
Inventor
Linda S. Hoggins
David Y. Liu
Andrew A. Protter
Original Assignee
Scios Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios Inc. filed Critical Scios Inc.
Publication of PL369019A1 publication Critical patent/PL369019A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL02369019A 2001-11-09 2002-11-08 Sposób leczenia zwłóknienia torbielowatego PL369019A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33820901P 2001-11-09 2001-11-09

Publications (1)

Publication Number Publication Date
PL369019A1 true PL369019A1 (pl) 2005-04-18

Family

ID=23323870

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02369019A PL369019A1 (pl) 2001-11-09 2002-11-08 Sposób leczenia zwłóknienia torbielowatego

Country Status (9)

Country Link
US (1) US20040009990A1 (pl)
EP (1) EP1453515A4 (pl)
JP (1) JP2005511616A (pl)
BR (1) BR0214020A (pl)
CA (1) CA2466665A1 (pl)
IL (1) IL161667A0 (pl)
PL (1) PL369019A1 (pl)
TR (1) TR200401028T2 (pl)
WO (1) WO2003041644A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040101398A (ko) * 2002-04-05 2004-12-02 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 점액 과다분비의 치료방법
US20060100432A1 (en) 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
JP5385605B2 (ja) * 2005-03-11 2014-01-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ結合カセットトランスポーターのモジュレーター
CA2624683A1 (en) * 2005-10-06 2007-04-19 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US7851476B2 (en) 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
MX2008009022A (es) * 2006-01-13 2008-09-24 Wyeth Corp 1h-indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina.
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
CN102850324A (zh) * 2006-08-07 2013-01-02 硬木药品公司 吲哚化合物
KR20120117905A (ko) 2010-01-28 2012-10-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 프로테아좀 활성을 향상시키는 조성물 및 방법
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
PT2707101T (pt) 2011-05-12 2019-05-30 Proteostasis Therapeutics Inc Reguladores da proteostase
EP2771001A4 (en) * 2011-10-25 2015-03-25 Merck Sharp & Dohme PIPERIDINYL-alkyne-orexin
WO2014116228A1 (en) 2013-01-25 2014-07-31 President And Fellows Of Harvard College Usp14 inhibitors for treating or preventing viral infections
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
NZ762856A (en) 2017-10-05 2020-07-31 Fulcrum Therapeutics Inc P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515891A (ja) * 1997-12-19 2002-05-28 スミスクライン・ビーチャム・コーポレイション 新規なピペリジン含有化合物
DE69929689T2 (de) * 1998-05-22 2006-11-02 Scios Inc., Fremont Heterocyclische Verbindungen und Verfahren zur Behandlung von Herzversagen und anderer Erkrankungen
US6340685B1 (en) * 1998-05-22 2002-01-22 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6589954B1 (en) * 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
JP2003500403A (ja) * 1999-05-21 2003-01-07 サイオス，インコーポレーテッド ｐ３８キナーゼのインヒビターとしてのインドール型誘導体

Also Published As

Publication number Publication date
EP1453515A2 (en) 2004-09-08
CA2466665A1 (en) 2003-05-22
EP1453515A4 (en) 2006-11-29
WO2003041644A2 (en) 2003-05-22
BR0214020A (pt) 2004-10-13
IL161667A0 (en) 2004-09-27
TR200401028T2 (tr) 2004-11-22
WO2003041644A3 (en) 2003-11-13
US20040009990A1 (en) 2004-01-15
JP2005511616A (ja) 2005-04-28

Similar Documents

Publication Publication Date Title
GB2360534B (en) Formation treatment method using deformable particles
EP1454664A4 (en) ONLINE GAME PROCEDURES
GB0014969D0 (en) Novel method of treatment
PL369019A1 (pl) Sposób leczenia zwłóknienia torbielowatego
IL159784A0 (en) Methods of treating liver fibrosis
GB0129976D0 (en) Treatment method
EP1667518A4 (en) TREATMENT OF MUCOVISCIDOSIS WITH GAMMA TOCOPHEROL
EP1299672A4 (en) POWER STEERING DEVICE
IL143366A0 (en) Treatment of renal fibrosis
GB0120147D0 (en) Treatment method
GB0105899D0 (en) Fibrosis reduction treatment
AU2002236116A1 (en) Method to treat soapy wastewater
GB0026838D0 (en) Treatment method
EP1328234A4 (en) METHOD FOR TREATING CYSTIC FIBROSE
GB0008921D0 (en) Method of treatment
AU2003291565A8 (en) Polyionenes for treating infections associated with cystic fibrosis
GB2381312B (en) Methods relating to treatment of atherosclerosis
HK1069330A (en) Method to treat cystic fibrosis
AU2001272902A1 (en) Treating musculoskeletal disorders using lp85 and analogs thereof
GB0104555D0 (en) New Therapeutic method
EP1303281A4 (en) METHODS OF TREATMENT
GB2399118B (en) Formation treatment method using deformable particles
GB0126253D0 (en) Treatment method
AU2002356131A1 (en) Treatment for cystic fibrosis
GB0103621D0 (en) The treatment of cystic fibrosis